Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorine-18 fexinidazole injection
- Development stage
- Unknown
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fluorine-18 fexinidazole injection (also known as Fluorine[18F] Fibrosuppressin Injection or LNC1007) is a radiopharmaceutical diagnostic imaging agent developed by Yantai Dongcheng Pharmaceutical Group and its subsidiary, LNC Pharma. It is a small-molecule radiotracer labeled with the positron-emitting isotope fluorine-18 (18F) designed to target fibroblast activation protein (FAP). FAP is a cell-surface serine protease that is highly overexpressed in the tumor microenvironment, particularly in cancer-associated fibroblasts (CAFs) of various solid tumors, while remaining minimally expressed in normal adult tissues. By binding specifically to FAP, this agent enables the non-invasive visualization and characterization of the tumor stroma using positron emission tomography (PET) imaging. This imaging modality is intended to improve the detection, staging, and treatment monitoring of FAP-positive solid tumors. The agent is currently undergoing Phase 2 clinical trials in China.
- Other names
- Fluorine[18F] Fibrosuppressin Injection[18F]Fibrosuppressin氟[18F]纤抑素注射液
02
Targets
FAP (Fibroblast activation protein alpha)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on fluorine-18 fexinidazole injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorine-18 fexinidazole injection.